Finally, our retrospective analysis was undertaken before the approval of adjuvant PD-L1 immunotherapy with durvalumab in stage III NSCLC after chemoradiotherapy [22, 23]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.